- Conditions
- Osteoarthritis
- Interventions
- Bupivacaine
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Not listed
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 955
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Trauma, Trauma Injury, Pain, Acute
- Interventions
- Bupivacaine Liposome Injection, Bupivacaine
- Drug
- Lead sponsor
- Chadrick Evans
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
- Conditions
- Postoperative Pain, Total Knee Arthroplasty, Nerve Block
- Interventions
- bupivacaine, saline
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Malignant Neoplasms of Female Genital Organs, Gynecologic Cancer
- Interventions
- Bupivacaine, Liposomal Bupivacaine, Oxycodone, Pill Diary, Symptom Questionnaire
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer Female
- Interventions
- Bupivacaine Hydrochloride, Placebo Drug, Pulsed Electromagnetic Field (PEMF) Device, Placebo Device, Ropivacaine Hydrochloride
- Drug · Other · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pain Control
- Interventions
- TAP block using Bupivacaine 0.5%, TAP block using Bupivacaine 0.25%, TAP block using Normal Saline
- Procedure
- Lead sponsor
- New York Presbyterian Brooklyn Methodist Hospital
- Other
- Eligibility
- Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Hyperalgesia, Secondary
- Interventions
- Bupivacaine Placebo, Clonidine Placebo, Bupivacaine, Clonidine
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Pain, Postoperative
- Interventions
- ACB, ACB + iPACK
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neonatal Neurobehavior, Breastfeeding Outcomes
- Interventions
- Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000, Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000, Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000, Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Postoperative Pain
- Interventions
- HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 3 more
- Conditions
- Total Shoulder Arthroplasty
- Interventions
- bupivacaine., Saline
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Post Operative Pain, Spinal Fusion
- Interventions
- Bupivacaine liposome injectable suspension, Bupivacaine Hydrochloride and Epinephrine Injection
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Pain
- Interventions
- liposomal bupivacaine, Bupivacaine
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Postoperative Pain
- Interventions
- TLC590, Liposomal Bupivacaine, Saline Placebo
- Drug
- Lead sponsor
- TLC Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • Bellaire, Texas • Houston, Texas + 1 more
- Conditions
- Blunt Chest Wall Trauma, Rib Fracture, Sternal Fracture
- Interventions
- Liposomal bupivacaine, 0.9% sodium chloride
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease, Hyperparathyroidism
- Interventions
- Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline, Marcaine
- Procedure · Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Arthroscopic Shoulder Surgery, Intra-articular Debridement, Subacromial Decompression, Acromioplasty, Acromioclavicular Joint Resection
- Interventions
- Methylprednisolone (40 mg depomedrol, 1ml, injection), Marcaine (4ml 0.5%, injection)
- Drug
- Lead sponsor
- Peter Chang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Femoral Neck Fractures, Intertrochanteric Fractures
- Interventions
- PENG, FICB
- Procedure
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Stress Urinary Incontinence
- Interventions
- Pudendal block
- Other
- Lead sponsor
- Michael Flynn
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Cardiac Surgery, Opioid Use, Unspecified
- Interventions
- Bupivacaine Injection, Liposomal bupivacaine, Saline
- Drug · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Appendicitis
- Interventions
- UGBRSB, Local Infiltration
- Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Postoperative Pain
- Interventions
- Liposomal bupivacaine, Placebo - injection
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Pain, Postoperative
- Interventions
- Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution, Bupivacaine HCl 0.5% Injectable Solution, primary total knee replacement
- Drug · Procedure
- Lead sponsor
- Rothman Institute Orthopaedics
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Total Shoulder Arthroplasty, Shoulder Osteoarthritis
- Interventions
- Interscalene catheter, Liposomal bupivacaine, Dexamethasone, Bupivacaine
- Device · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York